Scarica l'app Stockscreener
21.23
1.30%
-0.28
Dopo l'orario di chiusura:
21.20
-0.03
-0.14%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché KROS Giù?
Forum
Previsione
Precedente Chiudi:
$21.51
Aprire:
$21.09
Volume 24 ore:
572.14K
Relative Volume:
0.60
Capitalizzazione di mercato:
$646.79M
Reddito:
-
Utile/perdita netta:
$-168.05M
Rapporto P/E:
-4.1384
EPS:
-5.13
Flusso di cassa netto:
$-146.15M
1 W Prestazione:
-0.42%
1M Prestazione:
+23.00%
6M Prestazione:
+56.56%
1 anno Prestazione:
+12.75%
Intervallo 1D:
$20.73
$21.29
Intervallo di 1 settimana:
$20.73
$22.20
Portata 52W:
$9.12
$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Nome
Keros Therapeutics Inc
Settore
Industria
Telefono
617-314-6297
Indirizzo
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA
Confronta KROS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KROS
Keros Therapeutics Inc
|
21.23 | 655.33M | 0 | -168.05M | -146.15M | -5.13 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Keros Therapeutics Inc Stock (KROS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-10-20 | Iniziato | Wells Fargo | Overweight |
| 2025-06-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2025-01-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2025-01-17 | Downgrade | Wedbush | Outperform → Neutral |
| 2024-12-16 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-13 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-12 | Downgrade | BTIG Research | Buy → Neutral |
| 2024-12-12 | Downgrade | TD Cowen | Buy → Hold |
| 2024-12-12 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2024-11-05 | Iniziato | Jefferies | Buy |
| 2024-10-24 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-10-16 | Iniziato | Scotiabank | Sector Outperform |
| 2024-09-23 | Iniziato | Guggenheim | Buy |
| 2024-06-25 | Iniziato | Oppenheimer | Outperform |
| 2024-02-21 | Iniziato | William Blair | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2023-07-31 | Iniziato | Wedbush | Outperform |
| 2023-07-26 | Iniziato | BofA Securities | Buy |
| 2023-02-14 | Iniziato | Cowen | Outperform |
| 2022-10-18 | Iniziato | Truist | Buy |
| 2022-07-26 | Iniziato | BTIG Research | Buy |
| 2020-12-08 | Reiterato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | H.C. Wainwright | Buy |
| 2020-05-04 | Iniziato | Jefferies | Buy |
| 2020-05-04 | Iniziato | Piper Sandler | Overweight |
| 2020-05-04 | Iniziato | SVB Leerink | Outperform |
Mostra tutto
Keros Therapeutics Inc Borsa (KROS) Ultime notizie
TFG Asset Management GP Ltd Sells 55,000 Shares of Keros Therapeutics, Inc. $KROS - MarketBeat
Responsive Playbooks and the KROS Inflection - news.stocktradersdaily.com
What Makes Keros Therapeutics, Inc. (KROS) a Strong Momentum Stock: Buy Now? - sharewise.com
KROS vs. ARGX: Which Stock Is the Better Value Option? - Yahoo Finance
Stocks showing market leadership: Keros Therapeutics earns 92 RS rating - MSN
Keros Therapeutics, Inc. $KROS Shares Sold by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC - MarketBeat
Keros Therapeutics, Inc. $KROS Stock Holdings Lowered by Federated Hermes Inc. - MarketBeat
Myelofibrosis Market to Expand Significantly by 2034, States DelveInsight Report | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart.com
Stocks to watch: Keros Therapeutics sees relative strength rating rise to 82 - MSN
Would You Still Hold Keros Therapeutics Stock If It Fell 30%? - Trefis
Can Keros Therapeutics Stock Hold Up When Markets Turn? - Trefis
Keros Therapeutics (NASDAQ:KROS) Trading Up 12%Here's Why - MarketBeat
There's No Escaping Keros Therapeutics, Inc.'s (NASDAQ:KROS) Muted Revenues Despite A 30% Share Price Rise - 富途牛牛
How Keros Therapeutics Inc. stock benefits from tech adoptionWeekly Earnings Recap & Risk Adjusted Buy/Sell Alerts - Newser
Franklin Resources Inc. Grows Stake in Keros Therapeutics, Inc. $KROS - Defense World
Will Keros Therapeutics Inc. stock outperform growth indexesBull Run & Fast Momentum Entry Tips - Newser
Top investors say Keros Therapeutics Inc (KROS) ticks everything they need - setenews.com
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Understanding the Setup: (KROS) and Scalable Risk - news.stocktradersdaily.com
TD Cowen Downgrades Keros Therapeutics (KROS) - MSN
Keros Therapeutics (KROS) Gets a Hold from Bank of America Securities - The Globe and Mail
Bank of America Increases Keros Therapeutics (NASDAQ:KROS) Price Target to $19.00 - MarketBeat
Keros Therapeutics (NASDAQ:KROS) Price Target Raised to $19.00 at Bank of America - Defense World
B of A Securities Maintains Keros Therapeutics (KROS) Neutral Recommendation - Nasdaq
How Much Upside is Left in Keros Therapeutics (KROS)? Wall Street Analysts Think 34.24% - MSN
KROS or NVZMY: Which Is the Better Value Stock Right Now? - MSN
ExodusPoint Capital Management, LP's Strategic Acquisition of Ke - GuruFocus
Keros Therapeutics Reports Strong Revenue Growth - MSN
Keros Therapeutics Announces Final Results of Tender Offer - The Manila Times
Watkins Advises on Keros Therapeutics, Inc.’s US$194.4 Million Tender Offer - Latham & Watkins LLP
Latham & Watkins Advises on Keros Therapeutics, Inc.’s US$194.4 Million Tender Offer - Legal Desire Media and Insights
The Technical Signals Behind (KROS) That Institutions Follow - news.stocktradersdaily.com
Keros Therapeutics announces final results of tender offer - marketscreener.com
[SC TO-I/A] Keros Therapeutics, Inc. Amended Issuer Tender Offer | KROS SEC FilingForm SC TO-I/A - Stock Titan
Keros Therapeutics (NASDAQ:KROS) Shares Gap DownHere's Why - MarketBeat
Is Keros Therapeutics Inc. stock reversal real or fakeWeekly Investment Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Keros Therapeutics reports oversubscribed $194.4 million tender offer By Investing.com - Investing.com Nigeria
Can Keros Therapeutics Inc. stock maintain operating margins2025 Technical Patterns & Fast Entry High Yield Tips - newser.com
Keros to Repurchase 11 Million Shares in Oversubscribed Tender Offer - MarketScreener
Keros Therapeutics Reports Third Quarter 2025 Financial Results - Sahm
Keros Therapeutics reports oversubscribed $194.4 million tender offer - Investing.com
Keros Therapeutics Announces Preliminary Results of Tender Offer - The Manila Times
Wall Street Analysts See a 42.78% Upside in Keros Therapeutics (KROS): Can the Stock Really Move This High? - MSN
Keros Therapeutics, Inc. (NASDAQ:KROS) Held Back By Insufficient Growth Even After Shares Climb 26% - simplywall.st
Keros Therapeutics Inc Azioni (KROS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.36%
1.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):